HEAW:LSE:LSE-SPDR® MSCI World Health Care UCITS ETF GBP (GBP)

ETF | Others |

Last Closing

USD 49.425

Change

+0.38 (+0.78)%

Market Cap

USD 0.57B

Volume

998.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+0.58 (+0.22%)

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

+0.31 (+0.49%)

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

+8.30 (+0.09%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

+2.75 (+1.49%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-1,070.99 (-89.87%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.12 (+0.69%)

USD 592.18B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.09 (+0.67%)

USD 592.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+16.50 (+0.82%)

USD 330.91B

ETFs Containing HEAW:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.94% 59% D- 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.94% 58% F 59% D-
Trailing 12 Months  
Capital Gain 9.88% 44% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.88% 43% F 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.42% 39% F 48% F
Dividend Return 1.42% 38% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 3.15% 93% A 97% N/A
Risk Adjusted Return 45.22% 63% D 75% C
Market Capitalization 0.57B 72% C 61% D-

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.